Stay updated on Volitinib for Primary CNS Tumors Clinical Trial
Sign up to get notified when there's something new on the Volitinib for Primary CNS Tumors Clinical Trial page.

Latest updates to the Volitinib for Primary CNS Tumors Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision: v3.6.6 replaces v3.6.5 on the page, indicating a new build of the site's framework or styling. This update appears to be a backend/software change with no visible changes to the study information.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page revision identifier was updated from v3.6.4 to v3.6.5, indicating a new version of the page. This appears to be a maintenance/metadata update rather than a change to the study content.SummaryDifference0.0%

- Check37 days agoChange DetectedA new Phase I Savolitinib study title is added, expanding the scope to MET-activated CNS tumors and listing related drug names (Orpathys, HMPL504, AZD-6094). Minor eligibility wording changes (serum creatinine) and procedural updates (e.g., Sample Collection) are also reflected.SummaryDifference0.6%

- Check45 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, indicating a new build. The previous revision tag was removed.SummaryDifference0.0%

- Check66 days agoChange DetectedThe page revision indicator was updated from v3.6.2 to v3.6.3, signaling an update to the page template or platform components.SummaryDifference0.0%

- Check73 days agoChange DetectedSavolitinib study results have been posted and the study details have been updated. The Volitinib entry was removed, refocusing the page on the Savolitinib trial.SummaryDifference4%

Stay in the know with updates to Volitinib for Primary CNS Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Volitinib for Primary CNS Tumors Clinical Trial page.